|Topic||Strength and Limitations|
|Sources / references||1|
|Description / paper instructions
Group 5 is the paper that our professor assign to my group.My part is to write the limitation and the strength.My group partner give me some feedback on my part.They want me to mentions bias and confounding.Also,could you add some conflict of interests as well.
Strengths and Limitations
The article by Valsesia et al. (2019) has both strengths and limitations which should be taken into account to be able to evaluate the reliability and validity of the study and its findings.
While some strengths of the research were derived from the context, some strong sides of the study have been explicitly stated. First, one needs to mention that the study offers the most up to date evidence on the topic of obesity since the study results date back to 2018 while the article itself was published in 2019. Hence, the findings presented in the work are recent. Second, the research presents well-justified rationale of each component of the research procedure making the study replicable for other researchers who will be willing to conduct a similar project. To illustrate, the critical elements are presentation of materials and methods, overview of the DioGenes clinical study as a source for intervention and data collection, with a number of most critical variables being controlled, as well as detailed data analysis based on verified statistical models and interpretation procedures. Thus, one can regard this factor as strength of the article because the future researchers may have an opportunity to carry out the same research phases.
Third, the choice of study design and its components comprised the other strength. In particular, the article reported the empirical results of the two-phase intervention trial conducted across eight European centers with the research process been approved by the Ethics Committee that allows ensuring the ethical essence of the research processes and procedures when human beings as research participants are involved. In this way, the findings enabled suggesting the trustworthiness of the research findings and their generalizability based on the multicenter nature of the study. The assumption is also justified based on the well-organized discussion with a reference to the previous studies in the field suggesting the relevance of the current study in addressing the knowledge gap in line with the earlier findings, especially in light of cross-national comparisons. All the components together enable offering well-reasoned and supported with evidence rationale for acknowledging the fact that amylase 1 copy numbers cannot be regarded as notable biomarkers for obesity as well as type 2 diabetes.
The study also had some limitations undermining the quality of the findings. First, even though the research involved participants from different countries of the world, the validity of possible generalizations of the findings can be questioned. This is foremost due to the small sample size of the study comprising of 761 obese individuals. As a result, the potential for generalizations of the findings to the national populations is doubtful and requires testing the obtained results on the larger populations from both national and cross-national contexts to allow for valid generalizations on the topic.
Second, in spite of that the researchers specified that the findings can be considered as generalizable to the most weight maintenance recommendations given the outcomes of the interventions, there is a need to acknowledge the likelihood of individual factors as either contributing or preventing weight stabilization during the interventions. In this regard, the authors identified such a limitation as the lack of specific data on plasma enzymatic activities or postprandial glycemic response. Hence, these factors would enable more accurate findings on the topic.
Finally, regardless of that the researchers specified the strength of the study as being ‘one of a kind’ in exploring the topic of obesity, they provided no future research directions to outline the next steps to provide more comprehensive and credible evidence in eliminating the obesity challenge from both national and global perspectives.
Valsesia, A., Kulkarni, S. S., Marquis, J., Leone, P., Mironova, P., Walter, O. . . . O’Callahan, N. J. (2019). Salivary α-amylase copy number is not associated with weight trajectories and glycemic improvements following clinical weight loss: Results from a 2-phase dietary intervention study. American Journal in Clinical Nutrition, 109, 1029-1037.